Invest $10,000 into these ASX 200 shares in January

Market-beating returns could be on offer from these shares this year according to analysts.

| More on:
View of a business man's hand passing a $100 note to another with a bank in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Do you have $10,000 to invest into ASX 200 shares in January? If you do, then it could be worth considering the two shares in this article.

Let's see why they could be great options for investors this month:

Neuren Pharmaceuticals Ltd (ASX: NEU)

The first ASX 200 share to consider for a $10,000 investment in January is Neuren Pharmaceuticals.

It is a pharmaceuticals company that is focused on developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

Bell Potter is very bullish on the company. This is partly due to the potential of its NNZ-2591 therapy, which is under development at present. Its analysts said:

Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.

The broker currently has a buy rating and $25.00 price target on its shares. Based on its current share price of $12.20, this implies potential upside of just over 100% for investors between now and this time next year.

Xero Ltd (ASX: XRO)

Another ASX 200 share that could be a good option for a $10,000 investment in January is Xero.

It is a leader in cloud accounting across New Zealand, Australia, and the United Kingdom. Its online accounting software connects small business owners with their numbers, their bank, and advisors at anytime.

Goldman Sachs is a big fan of Xero. This is due to its huge total addressable market (TAM), which gives it a huge growth runway over the coming decades. Goldman highlights that Xero's TAM is over 100 million small to medium sized businesses (SMBs), which compares to its current subscriber base of 4.2 million. The broker said:

Xero is a Global Cloud Accounting SaaS player, with existing focuses in ANZ, UK, North American and SE Asian markets. We see Xero as very well-placed to take advantage of the digitisation of SMBs globally, driven by compelling efficiency benefits and regulatory tailwinds, with >100mn SMBs worldwide representing a >NZ$100bn TAM.

Given the company's pivot to profitable growth and corresponding faster earnings ramp, we see an attractive entry point into a global growth story with Xero our preferred large-cap technology name in ANZ – the stock is Buy rated.

Goldman has a buy rating and $201.00 price target on the company's shares. Based on its current share price of $168.17, this implies potential upside of approximately 20% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A young man looks at a stylised investment graph superimposed on an exterior office building backdrop.
Growth Shares

Where to invest $10,000 in ASX 200 stocks today

Analysts think these high-quality shares are in the buy zone for investors right now.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Growth Shares

Two ASX industrials shares with buy recommendations

One broker believes these growth shares are set to rise.

Read more »

Man smiling at a laptop because of a rising share price.
Growth Shares

I think these 2 exciting ASX growth shares are buys today

These stocks could deliver big returns.

Read more »

a man in a business suit and carrying a laptop stands smiling with hand in pocket outside a large office building in a city environment.
Growth Shares

Buy these 2 impressive ASX 200 shares in July: experts

Experts are bullish about these two businesses.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

3 ASX 200 shares set to dominate the next decade

Let's see why these shares could be great long term picks for Aussie investors.

Read more »

A group of businesspeople clapping.
Growth Shares

3 ASX growth shares with 10-year compounding potential

Let's see which shares are being tipped as buys for growth investors.

Read more »

Woman happy and relaxed on a sofa at a shop.
Growth Shares

Are these 2 top ASX growth shares buys?

Are these high-flyers still buys?

Read more »

Two university students in the library, one in a wheelchair, log in for the first time with the help of a lecturer.
Growth Shares

3 stellar ASX growth shares to buy with $7,000

Let's see why analysts are feeling bullish about these top stocks.

Read more »